Comparison of the effect of TAK-147 (zanapezil) and E-2020 (donepezil) on extracellular acetylcholine level and blood flow in the ventral hippocampus of freely moving rats

Brain Research

Volumn 1012, Issue 1-2, 2004, Pages 169-176

  Hatip Al Khatib, Izzettin ^a   Takashi, Arai ^b   Egashira, Nobuaki ^b   Iwasaki, Katsunori ^b   Fujiwara, Michihiro ^b  

^a PAMUKKALE UNIVERSITY   (Turkey)

^b FUKUOKA UNIVERSITY   (Japan)

Author keywords

Acetylcholine; Alzheimer's disease; E2020; Microdialysis; Neurotransmitters, modulators, transporters, and receptors; Ventral hippocampus; Zanapezil

Indexed keywords

ACETYLCHOLINE; DONEPEZIL; ZANEPEZIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD FLOW; CONTROLLED STUDY; DATA ANALYSIS; DEFECATION; DRUG POTENCY; FASCICULATION; GNAWING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; LASER DOPPLER FLOWMETRY; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; SALIVATION; SKELETAL MUSCLE;

ACETYLCHOLINE; ANIMALS; BENZAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR FLUID; HIPPOCAMPUS; INDANS; MALE; PIPERIDINES; RATS; RATS, WISTAR;

EID: 2442453242     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2004.03.067     Document Type: Article

References (37)

1. Akasofu S., Kosasa T., Kimura M., Kubota A. Protective effect of donepezil in a primary culture of rat cortical neurons exposed to oxygen-glucose deprivation. Eur. J. Pharmacol. 472:2003;57-63
2. Bartus R.T. On neurodegenerative, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp. Neurol. 163:2000;495-529
3. Brown D., Chisholm J.A., Owens J., Pimlott S., Patterson J., Wyper D. Acetylcholine muscarinic receptors and response to anti-cholinesterase therapy in patients with Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging. 30:2003;296-300
4. Doody S.R. Clinical benefits of a new piperidine-class acetylcholinesterase inhibitor. Eur. Neuropsychopharmacol. 9:1999;S67-S77
5. Flood J.F., Cherkin A. Scopolamine effects on memory retention in mice: a model of dementia? Behav. Neural Biol. 45:1986;169-184
6. Freo U., Pizzolato G., Dam M., Ori C., Battistin L. A short review of cognitive and functional neuroimaging studies of cholinergic drugs: implications for therapeutic potentials. J. Neural Transm. 109:2002;570-857
7. Hanyu H., Shimizu T., Tanaka Y., Takasaki M., Koizumi K., Abe K. Regional cerebral blood flow patterns and response to donepezil treatment in patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 15:2003;177-182
8. Hirai K., Kato K., Nakayama T., Hayako H., Ishihara Y., Goto G., Miyamoto M. Neurochemical effects of 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2, 3, 4, 5-tetrahydro-1H-1-benzazepin-8-yl)-1-propanone fumarate (TAK-147), a novel acetylcholinesterase inhibitor in rats. J. Pharmacol. Exp. Ther. 280:1997;1261-1269
9. Hutchison C.W., Nathan P.J., Mrazek L., Stough C. Cholinergic modulation of speed of early information processing: the effect of donepezil on inspection time. Psychopharmacology (Berl.). 155:2001;440-442
10. Ishihara Y., Goto G., Miyamoto M. Central selective acetylcholinesterase inhibitor with neurotrophic activity: structure-activity relationships of TAK-147 and related compounds. Curr. Med. Chem. 7:2000;341-354
11. Isoma K., Ishikawa M., Ohta M., Ogawa Y., Hasegawa H., Kohda T., Kamei J. Effects of T-82, a new quinoline derivative, on cholinesterase activity and extracellular acetylcholine concentration in rat brain. Jpn. J. Pharmacol. 88:2002;206-212
12. Kagitani F., Uchida S., Hotta H., Sato A. Effects of nicotine on blood flow and delayed neuronal death following intermittent transient ischemia in rat hippocampus. Jpn. J. Physiol. 50:2000;585-595
13. Kato K., Hayako H., Ishihara Y., Marui S., Iwane M., Miyamoto M. TAK-147, an acetylcholinesterase inhibitor, increases choline acetyltransferase activity in cultured rat septal cholinergic neurons. Neurosci. Lett. 260:1999;5-8
14. Kosasa T., Kuriya Y., Matsui K., Yamanishi Y. Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats. Eur. J. Pharmacol. 380:1999;101-107
15. Kosasa T., Kuriya Y., Matsui K., Yamanishi Y. Inhibitory effects of donepezil hydrochloride (E2020) on cholinesterase activity in brain and peripheral tissues of young and aged rats. Eur. J. Pharmacol. 386:1999;7-13
16. Kosasa T., Kuriya Y., Yamanishi Y. Effect of donepezil hydrochloride (E2020) on extracellular acetylcholine concentration in the central cortex of rats. Jpn. J. Pharmacol. 81:1999;216-222
17. Kosasa T., Kuriya Y., Matsui K., Yamanishi Y. Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer's disease, on cholinesterase activity in rats. Eur. J. Pharmacol. 389:2000;173-179
18. Matsuoka N., Maeda N., Ohkubo Y., Yamaguchi I. Differential effects of physostigmine and pilocarpine on the spatial memory deficits produced by two septo-hippocampal differentiations in rats. Brain Res. 559:1991;233-240
19. Miyamoto M., Takahashi H., Kato K., Hirai K., Ishihara Y., Goto G. Effects of 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2, 3, 4, 5-tetrahydro-1-H-1- benzazepin-8-yl)-1-propanone fumarate (TAK-147), a novel acetylcholinesterase inhibitor, on impaired learning and memory in animal models. J. Pharmacol. Exp. Ther. 277:1996;1292-1304
20. Morey C.E., Cilo M., Berry J., Cusick C. The effect of Aricept in persons with persistent memory disorder following traumatic brain injury: a pilot study. Brain Inj. 17:2003;809-815
21. Nakano S., Asada T., Matsuda H., Uno M., Takasaki M. Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease. J. Nucl. Med. 42:2001;1441-1445
22. Nakayama T., Takahashi H., Miyamoto M., Goto G., Nagai Y. Effect of TAK-147, a novel AChE inhibitor, on cerebral energy metabolism. Neurobiol. Aging. 17:1996;849-857
23. Nobili F., Koulibaly M., Vitali P., Migneco O., Mariani G., Ebmeier K., Pupi A., Robert P.H., Rodriguez G., Darcourt J. Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors. J. Nucl. Med. 43:2002;983-990
24. Nobili F., Vitali P., Canfora M., Girtler N., De Leo C., Mariani G., Pupi A., Rodriguez G. Effects of long-term donepezil therapy on rCBF of Alzheimer's patients. Clin. Neurophysiol. 113:2002;1241-1248
25. Ogura H., Kosasa T., Kuriya Y., Yamanishi Y. Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. Methods Find. Exp. Clin. Pharmacol. 22:2000;609-613
26. Ogura H., Kosasa T., Kuriya Y., Yamanishi Y. Donepezil, a centrally-acting acetylcholinesterase inhibitor, alleviates learning deficits in hypocholinergic models in rats. Methods Find. Exp. Clin. Pharmacol. 22:2000;89-95
27. Ogura H., Kosasa T., Kuriya Y., Yamanishi Y. Central and peripheral activity of cholinesterase inhibitors as revealed by yawning and fasciculation in rats. Eur. J. Pharmacol. 415:2001;157-164
28. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 4th ed. 1998;Academic Press, New York
29. Pratt R.D. Patient populations in clinical trials of the efficacy and tolerability of donepezil in patients with vascular dementia. J. Neurol. Sci. 203-204:2002;57-65
30. Scali C., Casamenti F., Bellucci A., Costagli C., Schmidt B., Pepe G. Effect of subchronic administration of metrifonate, rivastigmine and donepezil on brain acetylcholine in aged F344 rats. J. Neural Transm. 109:2002;1067-1080
31. Staff R.T., Gemmell H.G., Shanks M.F., Murray A.D., Venneri A. Changes in the rCBF images of patients with Alzheimer's disease receiving donepezil therapy. Nucl. Med. Commun. 21:2000;37-41
32. Takada Y., Yonezawa A., Kume T., Katsuki H., Kaneko S., Sugimoto H.A. Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. J. Pharmacol. Exp. Ther. 306:2003;772-773
33. Tallarida R.J., Murray R.B. Manual of Pharmacologic Calculations with Computer Programs. 2nd ed. 1987;Springer-Verlag, New York
34. Tsukada H., Kakiuchi T., Ando I., Ouchi Y.J. Functional activation of cerebral blood flow abolished by scopolamine is reversed by cognitive enhancers associated with cholinesterase inhibition: a positron emission tomography study in unanesthetized monkeys. J. Pharmacol. Exp. Ther. 281:1997;1408-1414
35. Wilkinson D., Doody R., Helme R., Taubman K., Mintzer J., Kertesz A., Pratt R.D. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology. 61:2003;479-486
36. Winer B.J. Statistical Principles in Experimental Design. 1971;514-603 McGraw-Hill, New York
37. Xu A., Chen Z., Yanai K., Huang Y., Wei E. Effect of 3-[1-(phenylmethyl)- 4-piperidinyl]-1-(2, 3, 4, 5-tetrahydro-1H-1-benzazepin-8-yl)-1-propanone fumarate, a novel acetylcholinesterase inhibitor, on spatial cognitive impairment induced by chronic cerebral hypoperfusion in rats. Neurosci. Lett. 331:2002;33-36